Pacira Biosciences, Inc. announced it has joined the PROBE (Patient Relevant Osteoarthritis endpoints using Big data Evaluation) Consortium, a pioneering initiative to revolutionize osteoarthritis (OA) research and improve patient care and outcomes on a global scale. Pacira is among a select group of U.S.-based companies to join the European Innovative Health Initiative (IHI) -funded public-private consortium, which brings together 38 partners from academia, industry, patient organizations, regulatory agencies, and health professionals with the goal of transforming the diagnosis and treatment of OA through the following initiatives: Creating a regulation-compliant database network to analyze unidentified patient data from multiple OA cohorts and registries. Using AI models to predict disease progression and support personalized medicine.
Developing novel multi-modal trial endpoints for better treatment evaluation. Providing tools for shared decision-making between patients and healthcare providers. With this approach, which will leverage data from over 70 million patients across diverse OA cohorts and real-world registries, PROBE aims to address major limitations in OA research and clinical care, including disease heterogeneity, fragmented datasets, and outdated trial designs.
Pacira delivers innovative, non-opioid treatments: EXPAREL®? (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA®? (triamcinolone acetonide extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®?o, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis.
